HIMS

Hims & Hers Health, Inc. (HIMS) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Hims & Hers Health, Inc. operates a consumer-first digital health platform providing access to prescription and non-prescription products, medical consultations, and laboratory testing. The company operates in the United States, United Kingdom, Canada, and the European Union, with recent strategic shifts in its U.S. weight loss offerings and significant international expansion through acquisitions.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 4% year-over-year, driven by a 969% surge in "Rest of the World" revenue ($78.2M vs $7.3M) due to recent acquisitions (Zava, Medici). Conversely, U.S. revenue declined 8% to $529.9M, primarily due to timing changes in revenue recognition for weight loss offerings and a shift to shorter shipping cadences.
• Profitability Decline: The company reported a net loss of $92.1 million compared to net income of $49.5 million in Q1 2025. This reversal was driven by a $33.9 million decrease in gross profit and a $102.3 million increase in operating expenses.
• Expense Increases: Operating expenses rose 27% to $475.1 million. Notable increases include General and Administrative expenses (up 126% to $109.7M) and Operations and Support (up 53% to $96.5M), driven by acquisition integration costs, employee compensation, and non-recurring charges.
• Restructuring Charges: The company recorded $33.5 million in non-recurring restructuring and other related charges ($28.5M in cost of revenue, $5.0M in operations) related to a strategic shift in its U.S. weight loss offering to focus on branded GLP-1 medications.
• Acquisitions: Completed the acquisition of YourBio ($153M purchase price) in January 2026 and announced the proposed acquisition of Eucalyptus (up to $1.15B consideration) in February 2026.

Guidance, Outlook, and Risks

• Strategic Shift: Management announced a strategic shift for U.S. weight loss offerings to align with global approaches, prioritizing branded GLP-1 medications over compounded alternatives. This transition is expected to impact gross margins in the short term.
• Legal Proceedings:
  • FTC Investigation: Active settlement negotiations regarding privacy, advertising, and cancellation practices. The company has accrued $15.0 million for probable losses, though the final liability could be materially higher.
  • SEC Investigation: The SEC opened an investigation in February 2026 regarding public statements on compounded semaglutide.
  • Novo Nordisk Litigation: A patent infringement lawsuit filed by Novo Nordisk in February 2026 was voluntarily dismissed without prejudice in March 2026.
• Cybersecurity: In early February 2026, the company experienced a cybersecurity incident involving unauthorized access via social engineering. Remediation is substantially complete.
• Regulatory Environment: The company faces evolving regulatory scrutiny regarding compounded GLP-1s, with the FDA and HHS issuing statements and referrals for investigation in early 2026.
• Liquidity: The company maintains $750.9 million in cash and investments and has a $175 million revolving credit facility with $162.4 million available. Management believes resources are sufficient for the next 12 months.

Investor Verification Checklist

• Verify the impact of the U.S. weight loss strategic shift on future gross margins and customer retention rates.
• Monitor the outcome of the FTC settlement negotiations and the SEC investigation regarding compounded semaglutide disclosures.
• Assess the integration progress and revenue contribution of recent international acquisitions (Zava, Medici, YourBio) and the proposed Eucalyptus deal.
• Review the company's ability to maintain profitability given the significant increase in operating expenses and the shift from compounded to branded GLP-1 products.
• Confirm the status of the cybersecurity incident remediation and any potential long-term reputational or financial impacts.